

Beth E. Borowsky, et al.
U.S. Serial No: Not Yet Known
(\$371 National Stage Application
of PCT/US00/14654, filed May 26, 2000)
Filed: Herewith
Page 2

Please replace the paragraph on page 54, lines 19-26 with the following paragraph:

--In one embodiment, the mammalian cell line is the CHO cell line designated CHO-ratSNORF33-7. This cell line was deposited on May 3, 2000, with the American Type Culture collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and was accorded ATCC Patent Deposit Designation No. PTA-1807.--

In the Claims:

Please cancel claims 16-18 and 38-168 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend claims 1, 33, and 34 as follows:

--1. (Amended) An isolated nucleic acid encoding a mammalian SNORF33 receptor, wherein the mammalian SNORF33 receptor has the amino acid sequence of the human SNORF33 receptor (SEQ ID NO: 6) or a sequence having above 75% amino acid sequence identity thereto and is activated by any of tyramine, tryptamine, or β -phenyl-ethylamine.--

Beth E. Borowsky, et al.
U.S. Serial No: Not Yet Known
(§371 National Stage Application
of PCT/US00/14654, filed May 26, 2000)
Filed: Herewith
Page 3

--33. (Amended) The CHO cell of claim 32 designated CHO-ratSNORF33-7 (ATCC Patent Deposit Designation No. PTA-1807).--

--34. (Amended) The 293 cell of claim 32 designated 293-ratSNORF33-731 (ATCC Patent Deposit Designation No. PTA-1806). --

Applicants attach hereto as **Exhibit 1** a Marked-up version of the amendments.

REMARKS

This application is a §371 national stage of PCT International Application No. PCT/US00/14654, filed May 26, 2000, designating the United States of America, which claims priority of U.S. Serial No. 09/413,433, filed October 6, 1999, and U.S. Serial No. 09/322,257, filed May 28, 1999. Accordingly, the parent application, PCT International Application No. PCT/US00/14654, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject §371 national stage application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

Claims 1-168 were pending in the subject application. By this Amendment applicants have canceled claims 16-18 and 38-168 without prejudice or disclaimer, amended claims 33 and 34 to